Results 81 to 90 of about 10,632 (179)

Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study. [PDF]

HIV Med
Gartland M, Wang X, Liao Q, Li B, Du F, Krystal M, Tenorio AR, Pierce A, Castillo-Mancilla JR.   +8 more
europepmc   +1 more source

Advancements in development of novel class of HIV protease inhibitors. [PDF]

Ann Med
Gu WG, Yin GZ, Zhang YP.
europepmc   +1 more source

Cardiometabolic impact of dolutegravir as second-line therapy: secondary analysis of a randomized controlled trial. [PDF]

AIDS
Nyein PP, Donoghoe MW, Eriobu N, Uche B, Kaplan R, Carey D, Brown D, Kundro M, Dharan NJ, Hanson J, Petoumenos K, Matthews GV, the D EFT study group.   +12 more
europepmc   +1 more source

Maintain, not obtain: rethinking HIV care in sub-Saharan Africa in the era of dolutegravir. [PDF]

Front Public Health
Perno CF, Orlando S, Majid NA, Sangare H, Luanga R, Roccucci M, Silaghi LA, Sidumo Z, Brambilla D, Ceffa S, Guidotti G, Ciccacci F.   +11 more
europepmc   +1 more source

Impact of HAART therapy on cognitive function in patients with HIV: a systematic review of randomized control trial. [PDF]

Ann Med Surg (Lond)
Al Diab Al Azzawi M, Alhamed AM, Almajed H, Ahmed WA, Alshahrani NNA, Idris IS, Aldayhani OB, Fallatah F, Bedaiwi RH.   +8 more
europepmc   +1 more source

Analysis of Viral Blips Through Week 192 of the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Studies of Doravirine-Based Regimens in Adults Living With Previously Untreated HIV-1. [PDF]

Open Forum Infect Dis
Molina JM, Orkin C, Paredes R, Xu ZJ, Su FH, Asante-Appiah E, Plank RM, Lahoulou R.   +7 more
europepmc   +1 more source

Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimens. [PDF]

AIDS
Marcelin AG, Soulie C, Wirden M, Gruber J, Prata Menezes N, Lim T, Barriere G, Descamps D, Charpentier C, Calvez V.   +9 more
europepmc   +1 more source

Laser Microinterferometry for API Solubility and Phase Equilibria: Darunavir as a Case Example. [PDF]

Pharmaceutics
Makarova V, Mandrik M, Antonov S.
europepmc   +1 more source

Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV. [PDF]

Antimicrob Agents Chemother
Tsirizani L, Waalewijn H, Szubert A, Mulenga V, Chabala C, Bwakura-Dangarembizi M, Chitsamatanga M, Rutebarika DA, Musiime V, Kasozi M, Lugemwa A, McIlleron HM, Burger DM, Gibb DM, Colbers A, Denti P, Wasmann RE, CHAPAS-4 trial team.   +17 more
europepmc   +1 more source

Evolution and forecasting of antiretroviral therapy utilisation in British Columbia: a population-level analysis of provincial drug treatment programme data, 2014-2024. [PDF]

BMJ Open
Lima VD, Mokhtari Jazi A, Montaner JSG.
europepmc   +1 more source